NCT06377982

Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy

Name: Clinical Trial NCT06377982
Creator: StemCyte Taiwan Co., Ltd.
Keywords: Cerebral Palsy, hUCB, Phase 1, biological, clinical trial

A Phase I, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Safety and Efficacy of Allogeneic Human Umbilical Cord Blood Infusion in Children With Cerebral Palsy

StemCyte Taiwan Co., Ltd.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cerebral Palsy
Drug/Device/Intervention: hUCB
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: StemCyte Taiwan Co., Ltd.
Funder: StemCyte International, Ltd.

Timeline & enrollment

Phase: Phase 1
Start date: Sep 01, 2024
End date: Dec 01, 2026
Enrollment: 12 participants

Primary outcome

safety-TEAE

Summary

A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy

ICD-10 classifications

Cerebral palsyOther cerebral palsyCerebral palsy, unspecifiedDyskinetic cerebral palsyAtaxic cerebral palsy

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06377982
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06377982 through Pure Global AI's free database. This Phase 1 trial is sponsored by StemCyte Taiwan Co., Ltd. and is currently Not yet recruiting. The study focuses on Cerebral Palsy. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.